Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohamed A.A.
dc.contributor.authorSoliman H.
dc.contributor.authorIsmail M.
dc.contributor.authorZiada D.
dc.contributor.authorFarid T.M.
dc.contributor.authorAref A.M.
dc.contributor.authorAl Daly M.E.
dc.contributor.authorAbd Elmageed Z.Y.
dc.contributor.otherModern Science and Arts University
dc.date.accessioned2020-01-09T20:42:03Z
dc.date.available2020-01-09T20:42:03Z
dc.date.issued2015-01
dc.descriptionSJR 2024 1.119 Q1 H-Index 92
dc.description.abstractBackground: Despite the incidence rate of pancreatic cancer (PC) is uncommon in developing countries, it is considered as one of the most lethal disease. Improving patients' survival requires diagnosis of the disease at early stage. Therefore, it is imperative to identify more specific and sensitive marker(s) to be used for early detection of PC. Objectives: Our aim is to evaluate the potential role of circulating ADH and MIC-1 to be used as diagnostic markers in Egyptian patients and assess their value either alone or combined with CA19-9 in early detection of PC. Methods: Alcohol dehydrogenase (ADH), macrophage inhibitory cytokine (MIC-1) and CA19-9 were measured by ELISA in serum procured from PC patients (n = 50) versus normal subjects (n = 20). Results: Our results demonstrate that the circulating levels of ADH, MIC-1 and CA19-9 in blood of PC were significantly higher than in healthy controls (HCs) (p < 0.001). The highest marker sensitivity observed at early stage was MIC-1 (90%) and specificity was ADH (83%). The level of all three markers was elevated significantly in early stage of PC in comparison to HCs. The addition of ADH and MIC-1 to CA19-9 significantly improved the efficacy of diagnosis (p = 0.023). Conclusion: Our data demonstrate that not only the combination of ADH and MIC-1 to CA19-9 can be used in early detection of PC but also can improve the overall quality of diagnosis of this lethal disease.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=26662&tip=sid&clean=0
dc.identifier.citationMohamed, A. A., Soliman, H., Ismail, M., Ziada, D., Farid, T. M., Aref, A. M., Al Daly, M. E., & Abd Elmageed, Z. Y. (2015). Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. Pancreatology, 15(1), 34–39. https://doi.org/10.1016/j.pan.2014.10.008 ‌
dc.identifier.doihttps://doi.org/10.1016/j.pan.2014.10.008
dc.identifier.issn14243903
dc.identifier.otherhttps://doi.org/10.1016/j.pan.2014.10.008
dc.identifier.urihttps://t.ly/1VVKE
dc.language.isoEnglishen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofseriesPancreatology ; Volume 15, Issue 1, January–February 2015, Pages 34-39
dc.subjectADH; CA19-9; Diagnostic markers; MIC-1; Pancreatic cancer; Specificity and sensitivity.
dc.titleEvaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic canceren_US
dc.typeArticleen_US
dcterms.isReferencedBySoliman, A.S., Zhang, Q., Saleh, T., Zarzour, A., Selim, M., Abdel-Fattah, M., Pancreatic cancer mortality in Egypt: Comparison to the United States pancreatic cancer mortality rates (2006) Cancer Detect Prev, 30 (5), pp. 473-479. , Epub 2006/10/28; Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Cancer statistics, 2005 (2005) CA Cancer J Clin, 55 (1), pp. 10-30. , Epub 2005/01/22; Poruk, K.E., Firpo, M.A., Adler, D.G., Mulvihill, S.J., Screening for pancreatic cancer: Why, how, and who? (2012) Ann Surg, 257 (1), pp. 17-26. , Epub 2012/08/17; Brand, R., The diagnosis of pancreatic cancer (2001) Cancer J, 7 (4), pp. 287-297. , Epub 2001/09/20; Duraker, N., Hot, S., Polat, Y., Hobek, A., Gencler, N., Urhan, N., CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice (2007) J Surg Oncol, 95 (2), pp. 142-147. , Epub 2007/01/31; Harsha, H.C., Kandasamy, K., Ranganathan, P., Rani, S., Ramabadran, S., Gollapudi, S., A compendium of potential biomarkers of pancreatic cancer (2009) PLoS Med, 6 (4), p. e1000046. , Epub 2009/04/11; Grantzdorffer, I., Carl-Mcgrath, S., Ebert, M.P., Rocken, C., Proteomics of pancreatic cancer (2008) Pancreas, 36 (4), pp. 329-336. , Epub 2008/04/26; Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., MacDonald, J.S., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer (2006) J Clin Oncol, 24 (33), pp. 5313-5327. , Epub 2006/10/25; Chrostek, L., Jelski, W., Szmitkowski, M., Puchalski, Z., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the human pancreas (2003) Dig Dis Sci, 48 (7), pp. 1230-1233. , Epub 2003/07/23; Riveros-Rosas, H., Julian-Sanchez, A., Pina, E., Enzymology of ethanol and acetaldehyde metabolism in mammals (1997) Arch Med Res, 28 (4), pp. 453-471. , Epub 1997/01/01; Jelski, W., Kutylowska, E., Laniewska-Dunaj, M., Orywal, K., Laszewicz, W., Szmitkowski, M., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with acute and chronic pancreatitis (2011) Exp Mol Pathol, 91 (2), pp. 631-635. , Epub 2011/07/30; Jelski, W., Kutylowska, E., Laniewska-Dunaj, M., Szmitkowski, M., Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as candidates for tumor markers in patients with pancreatic cancer (2011) J Gastrointestin Liver Dis, 20 (3), pp. 255-259. , Epub 2011/10/01; Bootcov, M.R., Bauskin, A.R., Valenzuela, S.M., Moore, A.G., Bansal, M., He, X.Y., MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily (1997) Proc Natl Acad Sci U S A, 94 (21), pp. 11514-11519. , Epub 1997/10/23; Koopmann, J., Buckhaults, P., Brown, D.A., Zahurak, M.L., Sato, N., Fukushima, N., Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers (2004) Clin Cancer Res, 10 (7), pp. 2386-2392. , Epub 2004/04/10; Ozkan, H., Demirbas, S., Ibis, M., Akbal, E., Koklu, S., Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases (2011) Pancreatology, 11 (3), pp. 295-300. , Epub 2011/07/16; Misek, D.E., Patwa, T.H., Lubman, D.M., Simeone, D.M., Early detection and biomarkers in pancreatic cancer (2007) J Natl Compr Canc Netw, 5 (10), pp. 1034-1041. , Epub 2007/12/07; Kaur, S., Chakraborty, S., Baine, M.J., Mallya, K., Smith, L.M., Sasson, A., Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer (2013) PLoS One, 8 (2), p. e55171. , Epub 2013/02/06; Ballehaninna, U.K., Chamberlain, R.S., Biomarkers for pancreatic cancer: Promising new markers and options beyond CA 19-9 (2013) Tumour Biol, 34 (6), pp. 3279-3292. , Epub 2013/08/21; Buxbaum, J.L., Eloubeidi, M.A., Molecular and clinical markers of pancreas cancer (2010) JOP, 11 (6), pp. 536-544. , Epub 2010/11/12; Kim, T.H., Han, S.S., Park, S.J., Lee, W.J., Woo, S.M., Yoo, T., CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer (2010) Int J Radiat Oncol Biol Phys, 81 (5), pp. e743-e748. , Epub 2010/12/07; Jelski, W., Zalewski, B., Szmitkowski, M., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer (2008) Dig Dis Sci, 53 (8), pp. 2276-2280. , Epub 2007/12/21; Goggins, M., Molecular markers of early pancreatic cancer (2005) J Clin Oncol, 23 (20), pp. 4524-4531. , Epub 2005/07/09
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S1424390314010047-main.pdf
Size:
708.61 KB
Format:
Adobe Portable Document Format